Showing results (121-130 of 134) with videos related to

Sort By:
Pageof 14
AIDS (London, England)|March 1, 1995
Safety and immunogenicity of a V3 loop synthetic peptide conjugated to purified protein derivative in HIV-seronegative volunteersA Rubinstein, H Goldstein, M Pettoello-Mantovani, et al.
The Journal of Infectious Diseases|August 1, 1993
Detection of enterobacterial lipopolysaccharides and experimental endotoxemia by means of an immunolimulus assay using both serotype-specific and cross-reactive antibodiesH Saxen, J Vuopio-Varkila, J Luk, et al.
Vaccine|June 2, 1998
Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccinesS Schwarzer, S Reibel, A B Lang, et al.
Vaccine|August 1, 1990
Studies in volunteers to evaluate candidate Shigella vaccines: further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei diseaseD A Herrington, L Van de Verg, S B Formal, et al.
Infection and Immunity|May 1, 1992
Safety, immunogenicity, and efficacy of a Plasmodium falciparum vaccine comprising a circumsporozoite protein repeat region peptide conjugated to Pseudomonas aeruginosa toxin AL F Fries, D M Gordon, I Schneider, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 29, 2000
Immunologic responses of HIV-1-infected study subjects to immunization with a mixture of peptide protein derivative-V3 loop peptide conjugatesA Rubinstein, Y Mizrachi, M Pettoello-Mantovani, et al.
Science (New York, N.Y.)|April 15, 1988
Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malariaJ C Sadoff, W R Ballou, L S Baron, et al.
Infection and Immunity|September 1, 1997
Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and PeruD N Taylor, C O Tacket, G Losonsky, et al.
Infection and Immunity|November 24, 1999
Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccinationC O Tacket, M B Cohen, S S Wasserman, et al.
Infection and Immunity|March 20, 1999
Expanded safety and immunogenicity of a bivalent, oral, attenuated cholera vaccine, CVD 103-HgR plus CVD 111, in United States military personnel stationed in PanamaD N Taylor, J L Sanchez, J M Castro, et al.
Pageof 14